Summary of Key Points Core Viewpoint - The company, Shaanxi Beiyuan Chemical Group Co., Ltd., has decided to adjust the implementation schedule of its fundraising investment projects due to objective factors such as macroeconomic conditions and industry cycle fluctuations, while ensuring that the project content, investment total, and scale remain unchanged [1][11][12]. Group 1: Fundraising Overview - The company approved the public offering of up to 361,111,112 new shares, with total fundraising amounting to 343,999.07 million yuan [1][2]. - As of December 31, 2024, the actual use of the raised funds is 102,829.73 million yuan [4][10]. Group 2: Project Delay Details - The completion dates for several projects, including the 120,000 tons/year glycine project and the intelligent factory basic platform construction, have been extended to June 2025 due to various delays [6][10]. - The company plans to further adjust the completion dates for several projects to June 2027, including the 100,000 tons/year CPE and 20,000 tons/year CPVC projects [6][10]. Group 3: Reasons for Delay - The glycine project is delayed due to the immature industrial production setup of the mixed solvent method and the need for further testing and equipment selection [7][10]. - The intelligent factory project is affected by the need for system optimization and compliance with safety standards [8][10]. - The salt production project faces market challenges due to limited demand and economic viability [9][10]. Group 4: Measures to Ensure Completion - The company is actively working on plans to utilize by-products from the glycine project and is optimizing project management to ensure timely completion [7][8]. - Detailed optimization plans and strategies are being developed to ensure the intelligent factory project progresses smoothly [8][10]. - The company is conducting thorough market analysis and technical research to validate the feasibility of the salt production project [9][10]. Group 5: Impact of Project Delay - The delay in fundraising investment projects is based on careful consideration of objective circumstances and does not involve changes to project implementation subjects, fundraising purposes, or investment scales, thus not adversely affecting the company's operations or shareholder interests [10][11].

Summary of Key Points Core Viewpoint - The company has decided to postpone the completion date of its HDI project from June 2025 to June 2026, while maintaining the original investment structure and project scope, to enhance the efficiency of fund utilization and align with market conditions [7][9]. Group 1: Fundraising Overview - The company issued 11.54 million convertible bonds on April 4, 2023, with a total fundraising amount of RMB 1,154 million, netting RMB 1,139.62 million after deducting issuance costs [1]. - The funds are managed in a dedicated account as per regulatory requirements, ensuring proper oversight and usage [2]. Group 2: Fund Utilization Status - As of April 30, 2025, the total investment in the HDI project reached RMB 2,106.72 million, with RMB 803.04 million sourced from the raised funds and RMB 1,303.67 million from the company's own funds, achieving 81.43% of the total committed investment [5][7]. - The project has partially commenced production, with ongoing investments to enhance capacity [5]. Group 3: Project Delay Details - The HDI project, which began construction in Q4 2019, was initially planned for a 4.5-year construction period, with partial production starting in June 2021 [7]. - The decision to delay the project completion is based on a careful assessment of the macroeconomic environment and industry trends, aiming to optimize investment timing and resource allocation [8]. Group 4: Impact of Delay - The postponement of the project is a strategic decision that does not affect the project's implementation structure or financial allocations, ensuring no adverse impact on the company's operations [9]. - The project aligns with the company's strategic direction and market demand, which is expected to enhance competitiveness and support high-quality growth [8]. Group 5: Approval Process - The decision to delay the project has been approved by the company's board and supervisory committee, adhering to necessary regulatory procedures without requiring shareholder approval [9].

Core Viewpoint - The company has decided to postpone the completion date of the "Marketing Channel Network Upgrade Project" to December 31, 2026, due to various internal and external factors affecting project implementation [3][5][6]. Fundraising Overview - The company raised a total of RMB 1,222.90 million through its initial public offering, with a net amount of RMB 1,135.28 million after deducting issuance costs [2]. - The funds are stored in a dedicated account as per regulatory requirements, ensuring proper management and usage [2]. Project Details - The total investment for the "Marketing Channel Network Upgrade Project" is RMB 120.10 million, which includes costs for office space acquisition, leasing, renovation, and equipment [4]. - The project aims to enhance the company's marketing network and management capabilities by establishing 8 new offices and upgrading 22 existing ones [4]. Delay Reasons - The delay is attributed to the macroeconomic environment and pharmaceutical industry policies, leading to a significant reduction in the actual need for new offices in specific provinces [4]. - The complexity of marketing strategies for various drug delivery methods has also contributed to the extended timeline [4]. Impact of Delay - The postponement is seen as a prudent decision that will not adversely affect the company's normal operations or alter the total investment, usage, or scale of the project [5][6]. - The company aims to improve the efficiency of fund usage and project implementation quality while adhering to regulatory guidelines [5][6]. Decision-Making Process - The decision to postpone was approved by the company's board and supervisory committee during meetings held on May 23, 2025, and does not require shareholder approval [5][6]. - The sponsor institution has confirmed that the postponement complies with relevant laws and regulations, ensuring no harm to the company's or shareholders' interests [7].

智能自控（002877）公告，公司第五届董事会第十五次会议审议通过了《关于部分募集资金投资项目延 期的议案》。公司决定对募集资金投资项目"开关控制阀制造基地项目"达到预计可使用状态的日期进行 延期。调整前预定可使用日期为2024年12月31日，调整后为2025年12月31日。此次延期基于审慎原则， 结合了募集资金投资项目的实际投资进度、当前市场环境及公司发展战略，不涉及项目实施主体、募集 资金投资用途及规模的变更。 ...

卓越新能公告，公司于2025年5月13日召开董事会和监事会，审议通过了关于部分募集资金投资项目延 期的议案。公司将"年产10万吨烃基生物柴油生产线项目"达到预定可使用状态的时间延长至2025年12 月。该项目原预计达到可使用状态日期为2023年6月，第一次变更后预计达到可使用状态日期为2025年6 月。因公司对项目建设方案进行优化论证调整，整体建设进度有所延后。项目延期未改变募投项目的内 容、投资用途、投资总额和实施主体，无需提交股东大会审议。 ...